

04-04-2003

Form PTO-1595  
(Rev. 10/021)  
OMB No. 0651-0027 (exp. 6/30/2005)



102410189

U. S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office

Tab settings   
Attorney Docket Nos.: TRNT 8314, TRNT 8347, TRNT 8322  
(Formerly: SGMD 8314, SGMD 8347, SGMD 8322)

Express Mail Label No. EV 246525549 US

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

## 1. Name of conveying party(ies):

Sigma-Aldrich Co. of Highland, IL

4.1.03

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other \_\_\_\_\_

August 26, 2002

Execution Date: \_\_\_\_\_

## 2. Name and address of receiving party(ies)

Trinity Biotech Manufacturing, Ltd.

Name: \_\_\_\_\_

Internal Address: \_\_\_\_\_

Street Address: 2823 Girls Road

City: Jamestown

State: NY

Zip: 14701

Additional name(s) & address(es) attached? ☐ Yes ☒ No

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No.(s) \_\_\_\_\_

B. Patent No.(s) 5,985,582; 6,391,609;

6,194,394

Additional number(s) attached ☐ Yes ☒ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Timothy B. McBride

Internal Address: \_\_\_\_\_

Senniger, Powers, Leavitt &amp; Roedel

Street Address: \_\_\_\_\_

One Metropolitan Square, 16th Floor

City: St. Louis State: MO Zip: 63102

## 6. Total number of applications and patents involved:

3

## 7. Total fee (37 CFR 3.41).....\$ 120.00

- ☒ Enclosed  
☐ Authorized to be charged to deposit account

## 8. Deposit account number:

19-1345

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

## 9. Signature.

Timothy B. McBride

Name of Person Signing

Signature

April 1, 2003

Date

04/03/2003 ECDPER 00000071 5965582

Total number of pages including cover sheet, attachments, and document: 7

01 FC:8021

120.00 GP

Mail documents to be recorded with required cover sheet information to:  
Commissioner of Patent & Trademarks, Box Assignments  
Washington, D.C. 20231

PATENT  
REEL: 013907 FRAME: 0533

## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment"), effective as of August 26, 2002, is from SIGMA-ALDRICH CO., a \_\_\_\_\_ corporation ("Assignor"), to TRINITY BIOTECH MANUFACTURING LTD., a private limited company organized under the laws of Ireland ("Assignee").

WITNESSETH:

COPY F

WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of the date hereof, by and between Sigma Diagnostics, Inc. ("Sigma") and Trinity Biotech plc (Trinity") (the "Purchase Agreement"), Assignor is required to assign to Assignee all right, title and interest in and to the patents, and all pending applications therefore, identified on Exhibit A attached hereto (collectively, the "Patents");

NOW, THEREFORE, for \$1.00 and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignor hereby quitclaims, sells, assigns, and transfers to Assignee all worldwide right, title and interest Assignor may have on the date of this Assignment in and to the Patents, together with (i) all income, royalties and fees payable on or after the date of this Assignment in respect to the Patents and (ii) all causes of action, claims and demands and other rights for, or arising from, any infringement, including past infringements, of the Patents, such Patents to be held and enjoyed by Assignee to the full end of the terms for which the Patents are granted. Except as specifically set forth in the Purchase Agreement, Assignor assigns the Patents to Assignee AS IS, without any warranty of any kind.
2. Assignor further agrees without further consideration to cause to be performed such other lawful acts and to be executed such further assignments and other lawful documents as Assignee may from time to time reasonably request to effect fully this Assignment and to permit Assignee to be duly recorded as the owner of the Patents and all other rights hereby conveyed.

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their respective authorized officers, effective as of the day and year first above written.

ASSIGNOR:

SIGMA-ALDRICH CO.

By: *Robert Monaghan*  
(Robert Monaghan)  
Its: \_\_\_\_\_

ASSIGNEE:

TRINITY BIOTECH MANUFACTURING LTD.

By: \_\_\_\_\_

Its: \_\_\_\_\_

COPY

F

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their respective authorized officers, effective as of the day and year first above written.

ASSIGNOR:

SIGMA-ALDRICH CO.

By: \_\_\_\_\_  
(Robert Monaghan)

Its: \_\_\_\_\_

ASSIGNEE:

TRINITY BIOTECH MANUFACTURING  
LTD.

By: M. J. U. COPY  
Its: DIRECTOR SECRETARY

# EXHIBIT A

## Patents

- a. U.S. Provisional Application 60/103,417 – Thromboplastin Reagents and Methods for Using such Reagents (Expired)
- b. U.S. Application 09/413,683 – Thromboplastin Reagents and Methods for Using such Reagents
- c. PCT Application PCT/US99/23369; International Application WO 00/20835 – Thromboplastin Reagents and Methods for Using such Reagents (EPO Application and National Applications in Australia, Canada and Japan pending)
- d. Australian Application 13118/00 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
- e. Canadian Application 2,342,606 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
- f. Japanese Application 2000-575903 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
- g. European Application 99956522.9 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
- h. U.S. Patent Application 08/987,038 – Improved Thrombin-based Assay for Antithrombin III
- i. Canadian Application 2,255,255 – Improved Thrombin-based Assay for Antithrombin III (Pending)
- j. European Application 98310023.1 – Improved Thrombin-based Assay for Antithrombin III (Pending)
- k. Australian Application 95156/98 – Improved Thrombin-based Assay for Antithrombin III
- l. Australia Application 72346/00 – Plasma Reference
- m. Japanese Application 349902/1998 – Improved Thrombin-based Assay for Antithrombin III (Pending)
- n. U.S. Patent Application 09/360,659 – Improved Thrombin-based Assay for Antithrombin III (Abandoned)
- o. U.S. Patent Application 09/108,732 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays
- p. U.S. Patent Application 09/771,195 – Methods for Quality Control of Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays Using Coagulation (Pending)
- q. PCT Application PCT/US99/13974 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (EPO Application and National Applications in Australia, Canada and Japan pending)
- r. Australian Application 45807/99 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays
- s. Canadian Application 2,334,582 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (Pending)
- t. Japanese Application 2000-558398 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (Pending)
- u. European Application 99928825.1 – Coagulation Controls for Prothrombin Time

COPY

F

# EXHIBIT A

COPY

## Patents

1.
  - a. U.S. Provisional Application 60/103,417 – Thromboplastin Reagents and Methods for Using such Reagents (Expired)
  - b. U.S. Application 09/413,683 – Thromboplastin Reagents and Methods for Using such Reagents
  - c. PCT Application PCT/US99/23369; International Application WO 00/20835 – Thromboplastin Reagents and Methods for Using such Reagents (EPO Application and National Applications in Australia, Canada and Japan pending)
  - d. Australian Application 13118/00 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
  - e. Canadian Application 2,342,606 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
  - f. Japanese Application 2000-575903 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
  - g. European Application 99956522.9 – Thromboplastin Reagents and Methods for Using such Reagents (Pending)
  - h. U.S. Patent Application 08/987,038 – Improved Thrombin-based Assay for Antithrombin III
  - i. Canadian Application 2,255,255 – Improved Thrombin-based Assay for Antithrombin III (Pending)
  - j. European Application 98310023.1 – Improved Thrombin-based Assay for Antithrombin III (Pending)
  - k. Australian Application 95156/98 – Improved Thrombin-based Assay for Antithrombin III
  - l. Australia Application 72346/00 – Plasma Reference
  - m. Japanese Application 349902/1998 – Improved Thrombin-based Assay for Antithrombin III (Pending)
  - n. U.S. Patent Application 09/360,659 – Improved Thrombin-based Assay for Antithrombin III (Abandoned)
  - o. U.S. Patent Application 09/108,732 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays
  - p. U.S. Patent Application 09/771,195 – Methods for Quality Control of Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays Using Coagulation (Pending)
  - q. PCT Application PCT/US99/13974 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (EPO Application and National Applications in Australia, Canada and Japan pending)
  - r. Australian Application 45807/99 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays
  - s. Canadian Application 2,334,582 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (Pending)
  - t. Japanese Application 2000-558398 – Coagulation Controls for Prothrombin Time (PT) and Activated Thromboplastin Time (APTT) Assays (Pending)
  - u. European Application 99928825.1 – Coagulation Controls for Prothrombin Time

F

- (PT) and Activated Thromboplastin Time (APTT) Assays (Pending)
- v. U.S. Provisional Application 60/248,116 – Assays, Reagents and Kits for Detecting or Determining the Concentration of Analytes (Expired)
- w. U.S. Application 10/012,280 – Assays, Reagents and Kits for Detecting or Determining the Concentration of Analytes (Pending)
- x. PCT Application (serial number not received) – Assays, Reagents and Kits for Detecting or Determining the Concentration of Analytes (Pending)
- y. U.S. Provisional Application 60/141,699 – Synthetic Peptide Immunogens and Antibodies Thereto (Expired)
- z. PCT Application PCT/US00/17609 – Synthetic Peptide Immunogens and Antibodies Thereto (EPO Application and National Applications in Australia, Canada and Japan pending).
- aa. U.S. Patent Application 09/605,006 – Synthetic Peptide Immunogens and Antibodies Thereto (Abandoned)
- bb. Australia Patent Application 63384/00 – Synthetic Peptide Immunogens and Antibodies Thereto (Abandoned)
- cc. Canadian Patent Application 2339404 – Synthetic Peptide Immunogens and Antibodies Thereto (Abandoned)
- dd. Japanese Application 2001-505944 – Synthetic Peptide Immunogens and Antibodies Thereto (Abandoned)
- ee. European Patent Application 00950257.6 – Synthetic Peptide Immunogens and Antibodies Thereto (Abandoned)

COPY

F